Lilly wins the backing of EU regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients https://t.co/x2fzm7e9j2 ...

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round https://t.co/9jEBW3iica https://t.co/9jEBW3iica ...

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round https://t.co/6dPt5RG6di https://t.co/6dPt5RG6di ...

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/1bBd93vmef https://t.co/Dtw8pt4XG9 ...

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round https://t.co/u4uHgFsXGJ https://t.co/u4uHgFsXGJ ...

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/QiTtfEYSjy https://t.co/XdRh7oCqF8 ...

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round https://t.co/U4pzFtDnCo https://t.co/U4pzFtDnCo ...

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Roundhttps://t.co/WmLCaxEKAO https://t.co/Xr9qN4bXJU ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/4AKaFgvboQ ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/EG83x9t9Fb ...